Recent progress of small molecular VEGFR inhibitors as anticancer agents

Mini-Reviews in Medicinal Chemistry

Volumn 11, Issue 1, 2011, Pages 18-31

  Xu, D ^a   Wang, T L ^a   Sun, L P ^a   You, Q D ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Anticancer; Inhibitor; Small molecular; Vascular endothelial growth factor receptor

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AAL 993; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; BIBF 1000; BMS 605541; CEDIRANIB; INTEDANIB; JNJ 17029259; KI 8751; KRN 633; LINIFANIB; MOTESANIB; PAZOPANIB; PEGAPTANIB; PROTEIN TYROSINE KINASE; RANIBIZUMAB; SEMAXANIB; SORAFENIB; SUNITINIB; TIVOZANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB;

ANGIOGENESIS; ARTICLE; CANCER RESEARCH; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650853253     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955711793564015     Document Type: Article

References (94)

1. Folkman, J.; D'Amore, P. A. Blood vessel formation: what is its molecular basis? Cell, 1996, 87, 1153-1155.
2. Klagsbrun, M.; Moses, M. A. Molecular angiogenesis. Chem. Biol.,1999, 6, R217-224.
3. Webster, K. A. Therapeutic angiogenesis for coronary artery disease: clinical trials of proteins, plasmids, adenovirus and stem cells. Future Cardiol, 2005, 1, 99-109.
4. Stegmann, T. J. FGF-1: a human growth factor in the induction of neoangiogenesis. Expert Opin Investig. Drugs, 1998, 7, 2011-2015.
5. Walsh, D. A. Angiogenesis and arthritis. Rheumatology (Oxford), 1999, 38, 103-112.
6. Pousa, I. D.; Mate, J.; Gisbert, J. P. Angiogenesis in inflammatory bowel disease. Eur. J. Clin. Invest., 2008, 38, 73-81.
7. Ferrara, N.; Alitalo, K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med., 1999, 5, 1359-1364.
8. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol., 2002, 29, 15-18.
9. Folkman, J.; Klagsbrun, M. Angiogenic factors. Science, 1987, 235, 442-447.
10. Folkman, J. Tumor angiogenesis: therapeutic implications. N EnglJ Med, 1971, 285, 1182-1186.
11. Folkman, J. What Is the Evidence That Tumors Are Angiogenesis Dependent? J. Natl. Cancer Inst., 1990, 82, 4-7.
12. Folkman, J. Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev, 1990, 9, 171-174.
13. Tonini, T.; Rossi, F.; Claudio, P. P. Molecular basis of angiogenesis and cancer. Oncogene, 2003, 22, 6549-6556.
14. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86, 353-364.
15. Kolibaba, K. S.; Druker, B. J. Protein tyrosine kinases and cancer. Biochim Biophys Acta, 1997, 1333, F217-248.
16. Risau, W. Mechanisms of angiogenesis. Nature, 1997, 386, 671-674.
17. Thomas, K. A. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem, 1996, 271, 603-606.
18. Ogawa, S.; Oku, A.; Sawano, A.; Yamaguchi, S.; Yazaki, Y.; Shibuya, M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem, 1998, 273, 31273-31282.
19. De Falco, S.; Gigante, B.; Persico, M. G. Structure and function of placental growth factor. Trends Cardiovasc Med, 2002, 12, 241-246.
20. Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J,1999, 13, 9-22.
21. Terman, B. I.; Carrion, M. E.; Kovacs, E.; Rasmussen, B. A.; Eddy, R. L.; Shows, T. B. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene, 1991, 6, 1677-1683.
22. Kowanetz, M.; Ferrara, N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res.,2006, 12, 5018-5022.
23. Tanigawa, N.; Amaya, H.; Matsumura, M.; Shimomatsuya, T.; Horiuchi, T.; Muraoka, R.; Iki, M. Extent of Tumor Vascularization Correlates with Prognosis and Hematogenous Metastasis in Gastric Carcinomas. Cancer Res., 1996, 56, 2671-2676.
24. Litz, J.; Krystal, G. W. Imatinib inhibits c-Kit-induced hypoxiainducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol. Cancer Ther.,2006, 5, 1415-1422.
25. Brown, L. F.; Berse, B.; Jackman, R. W.; Tognazzi, K.; Manseau, E. J.; Dvorak, H. F.; Senger, D. R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am. J. Pathol., 1993, 143, 1255-1262.
26. Olson, T. A.; Mohanraj, D.; Carson, L. F.; Ramakrishnan, S. Vascular Permeability Factor Gene Expression in Normal and Neoplastic Human Ovaries. Cancer Res., 1994, 54, 276-280.
27. Soulitzis, N.; Karyotis, I.; Delakas, D.; Spandidos, D. A. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol., 2006, 29, 305-314.
28. Brown, L. F.; Berse, B.; Jackman, R. W.; Tognazzi, K.; Manseau, E. J.; Senger, D. R.; Dvorak, H. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res., 1993, 53, 4727-4735.
29. Gille, J. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp. Dermatol., 2006, 15, 175-186.
30. Bellamy, W. T.; Richter, L.; Frutiger, Y.; Grogan, T. M. Expression of Vascular Endothelial Growth Factor and Its Receptors in Hematopoietic Malignancies. Cancer Res., 1999, 59, 728-733.
31. Fuh, G.; Li, B.; Crowley, C.; Cunningham, B.; Wells, J. A. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem, 1998, 273, 11197-11204.
32. Ruch, C.; Skiniotis, G.; Steinmetz, M. O.; Walz, T.; Ballmer-Hofer, K. Structure of a VEGF-VEGF receptor complex determined by electron microscopy. Nat. Struct. Mol. Biol., 2007, 14, 249-250.
33. Holmes, K.; Roberts, O. L.; Thomas, A. M.; Cross, M. J. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal, 2007, 19, 2003-2012.
34. Guo, D.; Jia, Q.; Song, H. Y.; Warren, R. S.; Donner, D. B. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J. Biol. Chem.,1995, 270, 6729-6733.
35. Waltenberger, J.; Claesson-Welsh, L.; Siegbahn, A.; Shibuya, M.; Heldin, C. H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol.Chem., 1994, 269, 26988-26995.
36. Cardones, A. R.; Banez, L. L. VEGF inhibitors in cancer therapy. Curr. Pharm. Des., 2006, 12, 387-394.
37. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambroso, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science, 1994, 265, 1093-1095.
38. Sathornsumetee, S.; Rich, J. N. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today (Barc), 2006, 42, 657-670.
39. Matsumori, Y.; Yano, S.; Goto, H.; Nakataki, E.; Wedge, S. R.; Ryan, A. J.; Sone, S. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol. Res., 2006, 16, 15-26.
40. Ciardiello, F.; Caputo, R.; Damiano, V.; Caputo, R.; Troiani, T.; Vitagliano, D.; Carlomagno, F.; Veneziani, B. M.; Fontanini, G.; Bianco, A. R.; Tortora, G. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res., 2003, 9, 1546-1556.
41. Sorbera, L. A.; Serradell, N.; Rosa, E.; Bolós, J.; Bayés, M. Cediranib. Drugs Future, 2007, 32, 577-589.
42. Wedge, S. R.; Kendrew, J.; Hennequin, L. F.; Valentine, P. J.; Barry, S. T.; Brave, S. R.; Smith, N. R.; James, N. H.; Dukes, M.; Curwen, J. O.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Kilburn, L. L.; Barnett, S.; Richmond, G. H. P.; Wadsworth, P. F.; Walker, M.; Bigley, A. L.; Taylor, S. T.; Cooper, L.; Beck, S.; Jurgensmeier, J. M.; Ogilvie, D. J. AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer. Cancer Res., 2005, 65, 4389-4400.
43. Baka, S.; Clamp, A. R.; Jayson, G. C. A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. ExpertOpin. Ther. Targets, 2006, 10, 867-876.
44. Nakamura, K.; Yamamoto, A.; Kamishohara, M.; Takahashi, K.; Taguchi, E.; Miura, T.; Kubo, K.; Shibuya, M.; Isoe, T. KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol. Cancer Ther., 2004, 3, 1639-1649.
45. Nakamura, K.; Taguchi, E.; Miura, T.; Yamamoto, A.; Takahashi, K.; Bichat, F.; Guilbaud, N.; Hasegawa, K.; Kubo, K.; Fujiwara, Y.; Suzuki, R.; Kubo, K.; Shibuya, M.; Isae, T. KRN951, a Highly Potent Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, Has Antitumor Activities and Affects Functional Vascular Properties. Cancer Res., 2006, 66, 9134-9142.
46. Kubo, K.; Shimizu, T.; Ohyama, S.; Murooka, H.; Iwai, A.; Nakamura, K.; Hasegawa, K.; Kobayashi, Y.; Takahashi, N.; Takahashi, K.; Kato, S.; Izawa, T.; Isoe, T. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. J. Med. Chem., 2005, 48, 1359-1366.
47. Harmange, J. C.; Weiss, M. M.; Germain, J.; Polverino, A. J.; Borg, G.; Bready, J.; Chen, D.; Choquette, D.; Coxon, A.; DeMelfi, T.; DiPietro, L.; Doerr, N.; Estrada, J.; Flynn, J.; Graceffa, R. F.; Harriman, S. P.; Kaufman, S.; La, D. S.; Long, A.; Martin, M. W.; Neervannan, S.; Patel, V. F.; Potashman, M.; Regal, K.; Roveto, P. M.; Schrag, M. L.; Starnes, C.; Tasker, A.; Teffera, Y.; Wang, L.; White, R. D.; Whittington, D. A.; Zanon, R. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. J. Med.Chem.,2008, 51, 1649-1667.
48. Fraley, M. E.; Arrington, K. L.; Buser, C. A.; Ciecko, P. A.; Coll, K. E.; Fernandes, C.; Hartman, G. D.; Hoffman, W. F.; Lynch, J. J.; McFall, R. C.; Rickert, K.; Singh, R.; Smith, S.; Thomas, K. A.; Wong, B. K. Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding. Bioorg. Med. Chem. Lett., 2004, 14, 351-355.
49. Bold, G.; Altmann, K. H.; Frei, J.; Lang, M.; Manley, P. W.; Traxler, P.; Wietfeld, B.; Bruggen, J.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Furet, P.; Hofmann, F.; Martiny-Baron, G.; Mestan, J.; Rosel, J.; Sills, M.; Stover, D.; Acemoglu, F.; Boss, E.; Emmenegger, R.; Lasser, L.; Masso, E.; Roth, R.; Schlachter, C.; Vetterli, W.New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J. Med. Chem., 2000, 43, 2310-2323.
50. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rosel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K. H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res., 2000, 60, 2178-2189.
51. Drevs, J.; Hofmann, I.; Hugenschmidt, H.; Wittig, C.; Madjar, H.; Muller, M.; Wood, J.; Martiny-Baron, G.; Unger, C.; Marme, D. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res, 2000, 60, 4819-4824.
52. Jain, R. K.; Duda, D. G.; Clark, J. W.; Loeffler, J. S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin.Pract. Oncol., 2006, 3, 24-40.
53. Duncton, M. A.; Piatnitski, E. L.; Katoch-Rouse, R.; Smith, L. M., 2nd; Kiselyov, A. S.; Milligan, D. L.; Balagtas, C.; Wong, W. C.; Kawakami, J.; Doody, J. F. Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg. Med. Chem. Lett., 2006, 16,1579-1581.
54. Manley, P. W.; Furet, P.; Bold, G.; Bruggen, J.; Mestan, J.; Meyer, T.; Schnell, C. R.; Wood, J.; Haberey, M.; Huth, A.; Kruger, M.; Menrad, A.; Ottow, E.; Seidelmann, D.; Siemeister, G.; Thierauch, K. H. Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J. Med. Chem., 2002, 45, 5687-5693.
55. Polverino, A.; Coxon, A.; Starnes, C.; Diaz, Z.; DeMelfi, T.; Wang, L.; Bready, J.; Estrada, J.; Cattley, R.; Kaufman, S.; Chen, D.; Gan, Y.; Kumar, G.; Meyer, J.; Neervannan, S.; Alva, G.; Talvenheimo, J.; Montestruque, S.; Tasker, A.; Patel, V.; Radinsky, R.; Kendall, R. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res., 2006, 66, 8715-8721.
56. Kiselyov, A. S.; Semenova, M.; Semenov, V. V. 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2. Bioorg. Med. Chem. Lett., 2009, 19, 1195-1198.
57. Garton, A. J.; Crew, A. P.; Franklin, M.; Cooke, A. R.; Wynne, G. M.; Castaldo, L.; Kahler, J.; Winski, S. L.; Franks, A.; Brown, E. N.; Bittner, M. A.; Keily, J. F.; Briner, P.; Hidden, C.; Srebernak, M. C.; Pirrit, C.; O'Connor, M.; Chan, A.; Vulevic, B.; Henninger, D.; Hart, K.; Sennello, R.; Li, A. H.; Zhang, T.; Richardson, F.; Emerson, D. L.; Castelhano, A. L.; Arnold, L. D.; Gibson, N. W. OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res., 2006, 66, 1015-1024.
58. Kiselyov, A. S.; Milligan, D.; Ouyang, X. Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates Bioorg. Med. Chem. Lett., 2007, 17, 3550-3557.
59. Honda, T.; Tajima, H.; Kaneko, Y.; Ban, M.; Inaba, T.; Takeno, Y.; Okamoto, K.; Aono, H. Conformation-activity relationship on novel 4-pyridylmethylthio derivatives with antiangiogenic activity. Bioorg. Med. Chem. Lett., 2008, 18, 2939-2943.
60. Nakamura, H.; Sasaki, Y.; Uno, M.; Yoshikawa, T.; Asano, T.; Ban, H. S.; Fukazawa, H.; Shibuya, M.; Uehara, Y. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases. Bioorg. Med. Chem. Lett., 2006, 16, 5127-5131.
61. Roskoski, R., Jr. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun, 2007, 356, 323-328.
62. Chow, L. Q.; Eckhardt, S. G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol., 2007, 25, 884-896.
63. Motzer, R. J.; Michaelson, M. D.; Redman, B. G.; Hudes, G. R.; Wilding, G.; Figlin, R. A.; Ginsberg, M. S.; Kim, S. T.; Baum, C. M.; DePrimo, S. E.; Li, J. Z.; Bello, C. L.; Theuer, C. P.; George, D. J.; Rini, B. I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2006, 24, 16-24.
64. Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med.Chem.,1998, 41, 2588-2603.
65. Manley, P. W.; Bold, G.; Bruggen, J.; Fendrich, G.; Furet, P.; Mestan, J.; Schnell, C.; Stolz, B.; Meyer, T.; Meyhack, B.; Stark, W.; Strauss, A.; Wood, J. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochim. Biophys.Acta., 2004, 1697, 17-27.
66. Sun, L.; Tran, N.; Liang, C.; Tang, F.; Rice, A.; Schreck, R.; Waltz, K.; Shawver, L. K.; McMahon, G.; Tang, C. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J. Med. Chem., 1999, 42, 5120-5130.
67. Morabito, A.; De Maio, E.; Di Maio, M.; Normanno, N.; Perrone, F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist, 2006, 11, 753-764.
68. Kulimova, E.; Oelmann, E.; Bisping, G.; Kienast, J.; Mesters, R. M.; Schwable, J.; Hilberg, F.; Roth, G. J.; Munzert, G.; Stefanic, M.; Steffen, B.; Brandts, C.; Muller-Tidow, C.; Kolkmeyer, A.; Buchner, T.; Serve, H.; Berdel, W. E. Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial rowth factor receptors. Mol. Cancer Ther., 2006, 5, 3105-3112.
69. Bisping, G.; Kropff, M.; Wenning, D.; Dreyer, B.; Bessonov, S.; Hilberg, F.; Roth, G. J.; Munzert, G.; Stefanic, M.; Stelljes, M.; Scheffold, C.; Muller-Tidow, C.; Liebisch, P.; Lang, N.; Tchinda, J.; Serve, H. L.; Mesters, R. M.; Berdel, W. E.; Kienast, J. Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups. Blood, 2006, 107, 2079-2089.
70. Roth, G. J.; Heckel, A.; Colbatzky, F.; Handschuh, S.; Kley, J.; Lehmann-Lintz, T.; Lotz, R.; Tontsch-Grunt, U.; Walter, R.; Hilberg, F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med.Chem.,2009, 52, 4466-4480.
71. Aronov, A. M.; McClain, B.; Moody, C. S.; Murcko, M. A. Kinaselikeness and kinase-privileged fragments: toward virtual polypharmacology. J. Med. Chem., 2008, 51, 1214-1222.
72. Traxler, P.; Allegrini, P. R.; Brandt, R.; Brueggen, J.; Cozens, R.; Fabbro, D.; Grosios, K.; Lane, H. A.; McSheehy, P.; Mestan, J.; Meyer, T.; Tang, C.; Wartmann, M.; Wood, J.; Caravatti, G. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res.,2004, 64, 4931-4941.
73. Munchhof, M. J.; Beebe, J. S.; Casavant, J. M.; Cooper, B. A.; Doty, J. L.; Higdon, R. C.; Hillerman, S. M.; Soderstrom, C. I.; Knauth, E. A.; Marx, M. A.; Rossi, A. M.; Sobolov, S. B.; Sun, J. Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity. Bioorg. Med. Chem. Lett., 2004, 14, 21-24.
74. Sorbera, L. A.; Bolós, J.; Serradell, N. Pazopanib Hydrochloride Drugs Future, 2006, 31, 585-589.
75. Sonpavde, G.; Hutson, T. E. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr. Oncol. Rep., 2007, 9, 115-119.
76. Emanuel, S.; Gruninger, R. H.; Fuentes-Pesquera, A.; Connolly, P. J.; Seamon, J. A.; Hazel, S.; Tominovich, R.; Hollister, B.; Napier, C.; D'Andrea, M. R.; Reuman, M.; Bignan, G.; Tuman, R.; Johnson, D.; Moffatt, D.; Batchelor, M.; Foley, A.; O'Connell, J.; Allen, R.; Perry, M.; olliffe, L.; Middleton, S. A. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional hemotherapeutic agents paclitaxel and doxorubicin in tumor xenograft models. Mol. Pharmacol., 2004, 66, 635-647.
77. Huang, S.; Li, R.; Connolly, P. J.; Emanuel, S.; Fuentes-Pesquera, A.; Adams, M.; Gruninger, R. H.; Seraj, J.; Middleton, S. A.; Davis, J. M.; Moffat, D. F. Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1). Bioorg. Med.Chem. Lett., 2007, 17, 2179-2183.
78. Kuo, G. H.; Prouty, C.; Wang, A.; Emanuel, S.; Deangelis, A.; Zhang, Y.; Song, F.; Beall, L.; Connolly, P. J.; Karnachi, P.; Chen, X.; Gruninger, R. H.; Sechler, J.; Fuentes-Pesquera, A.; Middleton, S. A.; Jolliffe, L.; Murray, W. V. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors. J. Med. Chem., 2005, 48, 4892-4909.
79. Claridge, S.; Raeppel, F.; Granger, M. C.; Bernstein, N.; Saavedra, O.; Zhan, L.; Llewellyn, D.; Wahhab, A.; Deziel, R.; Rahil, J.; Beaulieu, N.; Nguyen, H.; Dupont, I.; Barsalou, A.; Beaulieu, C.; Chute, I.; Gravel, S.; Robert, M. F.; Lefebvre, S.; Dubay, M.; Pascal, R.; Gillespie, J.; Jin, Z.; Wang, J.; Besterman, J. M.; MacLeod, A. R.; Vaisburg, A. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. Bioorg. Med. Chem. Lett., 2008, 18, 2793-2798.
80. Wu, Z.; Fraley, M. E.; Bilodeau, M. T.; Kaufman, M. L.; Tasber, E. S.; Balitza, A. E.; Hartman, G. D.; Coll, K. E.; Rickert, K.; Shipman, J.; Shi, B.; Sepp-Lorenzino, L.; Thomas, K. A. Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGFreceptor KDR. Bioorg. Med. Chem. Lett., 2004, 14, 909-912.
81. Wilhelm, S. M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H.; Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L. E.; Bollag, G.; Trail, P. A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 64, 7099-7109.
82. Adnane, L.; Trail, P. A.; Taylor, I.; Wilhelm, S. M. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol., 2006,407, 597-612.
83. Rini, B. I. Sorafenib. Expert Opin Pharmacother, 2006, 7, 453-461.
84. Albert, D. H.; Tapang, P.; Magoc, T. J.; Pease, L. J.; Reuter, D. R.; Wei, R. Q.; Li, J.; Guo, J.; Bousquet, P. F.; Ghoreishi-Haack, N. S.; Wang, B.; Bukofzer, G. T.; Wang, Y. C.; Stavropoulos, J. A.; Hartandi, K.; Niquette, A. L.; Soni, N.; Johnson, E. F.; McCall, J. O.; Bouska, J. J.; Luo, Y.; Donawho, C. K.; Dai, Y.; Marcotte, P. A.; Glaser, K. B.; Michaelides, M. R.; Davidsen, S. K. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther., 2006, 5, 995-1006.
85. Zhou, J.; Goh, B. C.; Albert, D. H.; Chen, C. S. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J Hematol. Oncol., 2009, 2, 33.
86. Heyman, H. R.; Frey, R. R.; Bousquet, P. F.; Cunha, G. A.; Moskey, M. D.; Ahmed, A. A.; Soni, N. B.; Marcotte, P. A.; Pease, L. J.; Glaser, K. B.; Yates, M.; Bouska, J. J.; Albert, D. H.; Black-Schaefer, C. L.; Dandliker, P. J.; Stewart, K. D.; Rafferty, P.; Davidsen, S. K.; Michaelides, M. R.; Curtin, M. L. Thienopyridine urea inhibitors of KDR kinase. Bioorg. Med. Chem Lett., 2007, 17, 1246-1249.
87. Dai, Y.; Guo, Y.; Frey, R. R.; Ji, Z.; Curtin, M. L.; Ahmed, A. A.; Albert, D. H.; Arnold, L.; Arries, S. S.; Barlozzari, T.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Guo, J.; Li, J.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Pease, L. J.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Wishart, N.; Davidsen, S. K.; Michaelides, M. R. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitorsJ. Med. Chem., 2005, 48, 6066-6083.
88. Ji, Z.; Ahmed, A. A.; Albert, D. H.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Diaz, G.; Glaser, K. B.; Guo, J.; Harris, C. M.; Li, J.; Marcotte, P. A.; Moskey, M. D.; Oie, T.; Pease, L.; Soni, N. B.; Stewart, K. D.; Davidsen, S. K.; Michaelides, M. R. 3-aminobenzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases. Journal of medicinal chemistry, 2008, 51, 1231-1241.
89. Revill, P.; Mealy, N.; Bayés, M.; Bozzo, J.; Serradell, N.; Rosa, E.Bolós, J. Axitinib. Drugs Future, 2007, 32, 389-398.
90. Ruggeri, B.; Singh, J.; Gingrich, D.; Angeles, T.; Albom, M.; Yang, S.; Chang, H.; Robinson, C.; Hunter, K.; Dobrzanski, P.; Jones-Bolin, S.; Pritchard, S.; Aimone, L.; Klein-Szanto, A.; Herbert, J. M.; Bono, F.; Schaeffer, P.; Casellas, P.; Bourie, B.; Pili, R.; Isaacs, J.; Ator, M.; Hudkins, R.; Vaught, J.; Mallamo, J.; Dionne, C. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res, 2003, 63, 5978-5991.
91. Borzilleri, R. M.; Bhide, R. S.; Barrish, J. C.; D'Arienzo, C. J.; Derbin, G. M.; Fargnoli, J.; Hunt, J. T.; Jeyaseelan, R., Sr.; Kamath, A.; Kukral, D. W.; Marathe, P.; Mortillo, S.; Qian, L.; Tokarski, J. S.; Wautlet, B. S.; Zheng, X.; Lombardo, L. J. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2. J. Med. Chem., 2006, 49, 3766-3769.
92. Potashman, M. H.; Bready, J.; Coxon, A.; DeMelfi, T. M., Jr.; DiPietro, L.; Doerr, N.; Elbaum, D.; Estrada, J.; Gallant, P.; Germain, J.; Gu, Y.; Harmange, J. C.; Kaufman, S. A.; Kendall, R.; Kim, J. L.; Kumar, G. N.; Long, A. M.; Neervannan, S.; Patel, V. F.; Polverino, A.; Rose, P.; Plas, S.; Whittington, D.; Zanon, R.; Zhao, H. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J. Med. Chem., 22007, 50,4351-4373.
93. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol., 2006, 2, 358-364.
94. Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Müller, G. Smallmolecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. ExpertOpin. Drug Discov., 2008, 3, 1427-1449.